Bengaluru: Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has announced that the Company has been featured on the prestigious Asia IP ELITE list for 2022 by lntellectual Asset Management (lAM) for its world-class Intellectual Property (IP) management and IP value creation in the Asia-Pacific region.
Biocon was the first and only pharmaceutical company from India to be featured on the ASIA IP ELITE list in 2016. Biocon Biologics debuted on the list in 2019. This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list, which recognizes companies across the Asia-Pacific region that demonstrate a sustained commitment to building best-in-class in-house lP functions and continuous excellence in lP value creation.
Shreehas Tambe, Deputy Chief Executive Officer, Biocon Biologics, said: “We are delighted that Biocon Biologics has been featured on the Asia IP ELITE 2022 list. This recognition is an endorsement of the Biocon Group’s commitment towards innovation and value creation for its stakeholders. Biocon and its subsidiaries have a strong track record of generating IP with over 1,000 granted patents for biologics till date.”
Biocon Biologics’ IP team was honoured at the latest edition of the IP Business Congress Asia, which is hosted by Intellectual Asset Management (IAM), the publishers of the world’s leading IP magazine IAM.
A record 80 organisations around the Asia-Pacific region featured in this year’s event, which was organized after a gap of two years.
“Biocon Biologics is a prime example of an Indian life sciences company that is built on R&D and innovation, even if much of its focus is based around challenging the entrenched patent positions of brand-name drug companies,” the IAM Special Report said.
“Most recently, the organisation’s biosimilars business has made it a central player in some of the most consequential global patent disputes in the cutting-edge biologics area. Along with [its] partner Viatris, Biocon Biologics won landmark U.S. Food and Drug Administration interchangeability approval for its biosimilar insulin [glargine] product, following extensive patent litigation with Sanofi,” the report added.